Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Jun 2;7(2):70.

Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review

Harold A Kessler  1
Affiliations
Review

Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review

Harold A Kessler. MedGenMed. .

Abstract

The development and widespread clinical use of coformulated abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) as Trizivir represented an important advance in the management of HIV-infected patients, especially those with adherence challenges. With a low pill burden, no food restrictions, limited drug-drug interactions, and a favorable resistance profile, ABC/3TC/ZDV remains an alternative option in the US Department of Health and Human Services Consensus Panel Guidelines as initial treatment in antiretroviral-naive patients. Recent data have shown ABC/3TC/ZDV to be less efficacious in suppressing and/or maintaining suppression of virologic replication compared with efavirenz-containing antiretroviral therapy. Although triple-nucleoside/nucleotide reverse transcriptase inhibitor (t-NRTI) combinations that do not contain a thymidine analog (ZDV or stavudine) have recently shown high virologic failure rates in clinical trials and clinical practice, t-NRTI regimens containing a thymidine analog have consistently been shown to be efficacious.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. April 7, 2005. Available at: http://aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf Accessed May 23, 2005.
    1. Gulick RM, Ribaudo HJ, Shikuma CM, et al. for the AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV infections. N Engl J Med. 2004;350:1850–1861. - PubMed
    1. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of once daily abacavir (ABC), lamivudine (3TC) and tenofovir DF (TDF) in treatment naive HIV-infected patients. Program and abstracts of the 2nd International AIDS Society Conference on Pathogenesis and Treatment; July 13–16, 2003; Paris, France. Abstract 43.
    1. Ruane P, Luber A, Akil B, et al. Factors influencing selection of K65R mutation among patients receiving tenofovir (TDF) containing regimens. Program and abstracts of the 2nd International AIDS Society Conference on Pathogenesis and Treatment; July 13–16, 2003; Paris, France. Abstract 582.
    1. MacArthur RD, Crane LR, Alvarez D, Fairfax M, Richmond D, Curtis G. Factors associated with selection of the K65R mutation: A retrospective chart review. Program and abstracts of the 2nd International AIDS Society Conference on Pathogenesis and Treatment; July 13–16, 2003; Paris, France. Abstract 835.

MeSH terms

LinkOut - more resources